Full-Time

Sr. Scientist

Immuno-Oncology Discovery

Confirmed live in the last 24 hours

Legend Biotech

Legend Biotech

1,001-5,000 employees

Develops and commercializes cell therapies

Biotechnology
Healthcare

Senior

Philadelphia, PA, USA

Category
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD degree in biological sciences (Immunology, Immuno-Oncology, cancer biology) or related field is required.
  • Senior Scientist- PhD +3 years of industry experience.
  • Scientist- PhD + 0-2 years of post PhD experience.
  • In depth knowledge of T cell development, signaling and differentiation/exhaustion is required.
  • Proficiency in conventional immunological techniques such as primary T cell isolation, gene editing/transduction, expansion, ELISA, cell sorting and flow cytometry is required.
  • Experience in CAR-T animal models, in vivo study design and execution is a strong plus.
  • Experience of high-throughput assay development or screening is preferred but not required.
  • Proficiency in single cell transcriptome analysis and data interpretation is a plus.
  • In depth knowledge in topics such as human tumor microenvironment (TME), tumor-infiltrating-lymphocytes (TIL), tertiary lymphoid structures (TLS), Immune Checkpoint Blockade (ICB) is preferred.
  • Knowledge in GVHD and transplant rejection mechanisms is a plus.
  • Innovation in cell therapy space is preferred as evidenced by publications and patents.
  • Language: English
Responsibilities
  • Design and execute CAR-T cell functional assays.
  • Phenotypic analysis of T cell differentiation markers.
  • Handling and engineering human and murine T cells as well as various cancer cells.
  • Analyze and interpret data, troubleshooting, present to and engage cross-functional teams.
  • Stay abreast of the latest advancement of cell therapy in solid tumor. Develop relevant insight in selected disease area.

Legend Biotech develops and commercializes cell therapies aimed at treating serious diseases, particularly cancers like hematological malignancies and solid tumors. Their approach is technology agnostic, allowing them to explore various methods to find effective treatments. The company operates in the personalized medicine sector, focusing on discovering, developing, and bringing new therapies to market. They generate revenue through licensing and selling their therapies, including CAR-T therapies, which involve modifying a patient's own cells to combat cancer. Legend Biotech emphasizes transparency with investors, regularly updating them on financial results and business developments.

Company Stage

IPO

Total Funding

$146.4M

Headquarters

Franklin Township, New Jersey

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

40%

2 year growth

102%
Simplify Jobs

Simplify's Take

What believers are saying

  • CARVYKTI® received FDA and European Commission approval for expanded use in multiple myeloma.
  • Legend Biotech is expanding R&D with a new facility in Philadelphia.
  • Collaboration with Multiply Labs aims to automate and improve cell therapy manufacturing.

What critics are saying

  • Increased competition from Amgen's Imdelltra could impact Legend's market share.
  • Expansion into new R&D facilities may strain financial resources.
  • Dependency on external technology through partnerships like MaxCyte could pose risks.

What makes Legend Biotech unique

  • Legend Biotech focuses on personalized cell therapies for hard-to-treat cancers.
  • The company is technology agnostic, exploring multiple platforms for effective treatments.
  • Legend Biotech's CARVYKTI® is the first BCMA-targeted CAR-T therapy approved for second-line treatment.

Help us improve and share your feedback! Did you find this helpful?